Cancer Therapy : Preclinical Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative , AD-01 , via the CD 44 Pathway

@inproceedings{McClements2013CancerT,
  title={Cancer Therapy : Preclinical Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative , AD-01 , via the CD 44 Pathway},
  author={L McClements and Anita Yakkundi and Angelos Papaspyropoulos and Hannah Harrison and Matthew P. Ablett and Puthen V. Jithesh and Hayley D. McKeen and Rachel Bennett and Christopher Donley and Adrien Kissenpfennig and Stuart A McIntosh and Helen O McCarthy and Eric O'neill and Robert B Clarke and Tracy Robson},
  year={2013}
}
Purpose: FK506-binding protein like (FKBPL) and its peptide derivative, AD-01, have already shown tumor growth inhibition and CD44-dependent antiangiogenic activity. Here, we explore the ability of AD-01 to target CD44-positive breast cancer stem cells (BCSC). Experimental Design: Mammosphere assays and flow cytometry were used to analyze the effect of FKBPL overexpression/knockdown and AD-01 treatment other anticancer agents on BCSCs using breast cancer cell lines (MCF-7/MDA-231/ZR-75… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011
VIEW 5 EXCERPTS

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2007
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Cancer stem cells: The challenges ahead

  • Nature Cell Biology
  • 2013
VIEW 1 EXCERPT